Why the study?
Device-related thrombosis due to direct blood contact with the device justifies antithrombotic therapy following LAAO, but the optimal post-LAAO antithrombotic regimen remains controversial.
Does antithrombotic therapy reduce thromboembolic events and major bleeding in atrial fibrillation patients after left atrial appendage occlusion?
Does antithrombotic therapy reduce thromboembolic events and major bleeding in atrial fibrillation patients after left atrial appendage occlusion?
DOACs may offer the best balance of efficacy and safety for post-LAAO antithrombotic therapy, though individualized regimens based on bleeding risk are necessary.
Answers are grounded in this paper and cite their sources.
May inform individualized post-LAAO regimens in AF; leaves open optimal strategy pending randomized trials.
INTRODUCTION: Left atrial appendage occlusion (LAAO) represents a strategy to minimize thromboembolic risk in atrial fibrillation (AF) patients. However, LAAO carries some risks of periprocedural bleeding, device embolization, peri-device leaks or device-related thrombosis; the latter is due to direct blood contact with the device, justifying and represents the rationale behind antithrombotic therapy following LAAO. AREAS COVERED: A comprehensive literature search (PubMed, Web of Science, Cochrane) has been performed up to November 2024. Antithrombotic drugs after LAAO include vitamin K antagonists (VKA), direct oral anticoagulants (DOAC), antiplatelet drugs, and their combinations. Initially, high-intensity regimens were implemented, while current strategies prioritize simplified approaches to promote device healing without increasing the bleeding risk. The aims of our review were to define the rationale and implications for post-LAAO antithrombotic therapy and provide an overview of current evidence on various antithrombotic regimens. EXPERT OPINION: The optimal post-LAAO antithrombotic regimen remains controversial, highlighting the need for randomized trials on this topic. Current data suggest that DOACs have the lowest probability of thromboembolic events and major bleeding, while DAPT may be preferred in patients who do not tolerate OAC; finally, single antiplatelet therapy or no antithrombotic therapy are alternative options for patients at high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Raffo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: